Prosecution Insights
Last updated: April 19, 2026
Application No. 17/923,115

SYSTEMS AND METHODS FOR REMOVING BIOMATERIAL IMPLANTS

Non-Final OA §112
Filed
Nov 03, 2022
Examiner
PRICE, NATHAN R
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Contraline Inc.
OA Round
1 (Non-Final)
52%
Grant Probability
Moderate
1-2
OA Rounds
4y 4m
To Grant
92%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allow Rate
261 granted / 498 resolved
-17.6% vs TC avg
Strong +39% interview lift
Without
With
+39.3%
Interview Lift
resolved cases with interview
Typical timeline
4y 4m
Avg Prosecution
50 currently pending
Career history
548
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
39.6%
-0.4% vs TC avg
§102
31.4%
-8.6% vs TC avg
§112
20.3%
-19.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 498 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment This office action is responsive to the amendment filed on 10/2/25. As directed by the amendment: 30, 31, and 33 have been amended, 1-29 and 34-61 have been cancelled, and new claims 62-77 have been added. Thus, claims 30-33 and 62-77 are presently pending in this application. Election/Restrictions Applicant’s election without traverse of Group III (claims 30-33 and 62-77) in the reply filed on 10/2/25 is acknowledged. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 30-33 and 62-77 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Specifically, the specification and disclosure as a whole does not provide adequate description of any particular methodology for causing the inward collapse/contraction of the implant, and does not establish how displacing a central portion of an implant would be performed such that it causes an outer perimeter of the implant to contract and collapse, as claimed in independent claim 30 and its dependent claims. The disclosure as a whole does not elaborate beyond what is claimed, with arguably the most detailed description of this methodology being found in par. 1061, which states that “the tool member 1650 traverses an entire length of the implant 1100 to create a tunnel (not shown) such that an outer surface of the implant 1100 collapses inwards towards the tunnel and an effective outer diameter of the implant is smaller than an inner diameter of the body lumen BL.” Additionally, levels of ordinary skill in the art would not have permitted the ordinary artisan to immediately envisage the claimed effect of contraction and collapse of the implant to result from displacing a central portion of the implant. For example, Lee-Sepsick et al. (US 20130220335) discloses in examples in fig. 6B and 6D advancing an instrument into/through an occlusion to displace some of the occlusion, but does not correlate this activity to collapsing or contracting the occlusion. Elsewhere, Efremkin (US 20190142453) discloses a methodology for removing a central portion of an occlusion using an ablative element 20 (see fig. 6-7A), but notes that since this element only removes a central portion of the occlusion, an additional element 65 must also be used to remove remaining outer portions of the occlusion adjacent to the vessel wall (see fig. 7A). Thus, the disclosure as a whole appears to lack sufficient particularity of description with regard to this methodology such that one having ordinary skill in the art would recognize that the inventor had possession of the claimed invention at the time of filing. Claims 30-33 and 62-77 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Independent claim 30 and its dependent claims broadly recite a cause and effect relationship between displacing a central portion of an implant and contracting and collapsing the implant toward a center. Neither the specification nor the claims provide direction for how displacing a central portion as claimed will cause the claimed central contraction/collapse, and fail to direct any particular methodology for causing the contraction or collapse. In contrast, the state of the prior art which would inform one having ordinary skill in the art appears to envision removal of material centrally from an implant without particularly associating such removal with collapse or contraction of the implant centrally; see in particular Lee-Sepsick et al. (US 20130220335) in the examples of fig. 6B and 6D where an instrument is advanced into/through an implant thereby displacing a central portion of the implant without correlating the activity to a collapse or contraction of the implant. See also Efremkin (US 20190142453) which discloses a methodology for removing a central portion of an occlusion using an ablative element 20 (see fig. 6-7A), but notes that since this element only removes a central portion of the occlusion, an additional element 65 must also be used to remove remaining outer portions of the occlusion adjacent to the vessel wall (see fig. 7A; par. 0075). Thus, it does not appear based on the state of the prior art that one having ordinary skill in the art would inherently correlate removal of central material of an implant to the inward contraction/collapse of the implant, as claimed and disclosed, and further would not understand implementing this claimed relationship without further direction from the inventor. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to NATHAN R PRICE whose telephone number is (571)270-5421. The examiner can normally be reached Mon-Fri 8:00am-4:00pm Eastern time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Tsai can be reached at 571-270-5246. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NATHAN R PRICE/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Nov 03, 2022
Application Filed
Feb 04, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599365
STABILIZING TRANSNASAL BALLOON SHEATH
2y 5m to grant Granted Apr 14, 2026
Patent 12599720
REAL TIME DETECTION AND MONITORING OF FLUID VOLUME AND FLOW RATE
2y 5m to grant Granted Apr 14, 2026
Patent 12594407
PREPARATION DELIVERY ASSEMBLY AND DEVICE HAVING MULTIPLE NEEDLES
2y 5m to grant Granted Apr 07, 2026
Patent 12576246
CATHETER SYSTEM HAVING A GUIDEWIRE SLIDER
2y 5m to grant Granted Mar 17, 2026
Patent 12502516
DISINFECTION DEVICE FOR FEMALE CONNECTORS
2y 5m to grant Granted Dec 23, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
52%
Grant Probability
92%
With Interview (+39.3%)
4y 4m
Median Time to Grant
Low
PTA Risk
Based on 498 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month